A transdermal therapeutic system which is free of fibrous constituents, and a method for the production of such a transdermal therapeutic system A preparation containing active substance is applied by a printing method onto the pressure-sensitive adhesive layer of the transdermal therapeutic system.

Formulations and methods for providing progestin-only contraception to a woman including transdermally administering to a woman a formulation having a contraceptively effective amount of progestin-only hormonal agents as part of a contraceptive regimen.

A transdermal patch contains a water-based solution containing electrolytes, vitamins, and at least one permeation enhancer. The water-based solution also acts as an adhesive matrix which binds the patch together. The solution is transferred to the body via an embossed release liner. In use, the permeation of electrolytes into the bloodstream improves the body's ability to manage hydration. The permeation enhancer increases the porosity of the skin in contact with the transdermal patch to make possible the permeation of the solution into the body. Critical proportions of solvent, solutes, and permeation enhancers are disclosed which have been found to make permeation of otherwise non-absorbable ingredients possible.

Pharmaceutical formulations of novel indole compounds and psilocybin analogs are manufactured, provided in novel oral, transdermal, and nasal pharmaceutical compositions for use to treat neurological, mood or abuse diseases and disorders.

Stretchable, occlusive backing layers for transdermal drug delivery systems are disclosed, that maintain occlusivity after stretching. The backing layers are comprised of a stretchable backing material provided with an occlusive coating comprising a styrene-isoprene-styrene block copolymer and tackifier. Also described are transdermal drug delivery systems having such backing layers, including transdermal drug delivery systems for non-steroidal anti-inflammatory drugs (NSAIDs), and methods of making and using such backing layers and transdermal drug delivery systems.

The present invention relates to transdermal drug delivery system of pharmaceutical compositions, which have a satisfactory in-vitro performance and good bioavailability. In particular, the transdermal pharmaceutical composition of clobazam in the present invention includes a micro-emulsion in liquid or semi solid form, in a dosage form adapted for transdermal delivery (e.g., transdermal patch) for treatment of certain types of epilepsy and anxiety for continues application.

A transdermal delivery system for systemic delivery of donepezil is described, where the system comprises an adhesive matrix drug reservoir layer comprised of a copolymer of acrylic acid/vinyl acetate, triethyl citrate, and donepezil base generated in situ by reaction of donepezil HCl and an alkaline salt. The system is provided for treatment of Alzheimer's disease, and achieves transdermal delivery of the therapeutic agent at steady state that is bioequivalent to administration of the therapeutic agent orally.

The present invention provides a composition for external application comprising baclofen or a salt thereof, specifically baclofen hydrochloride with high transdermal absorbability and stability, and a method of stabilizing a preparation comprising baclofen or a salt thereof.

Provided is a transdermal absorption preparation that shows superior skin permeability of a drug and that does not easily cause cold flow. A transdermal absorption preparation having a drug-containing layer containing a drug and a polymer, wherein 50-100 wt % of the polymer in the drug-containing layer is a polymer having a glass transition temperature of 30° C.-200° C., and the drug in the drug-containing layer is in an amorphous state.

An external patch that contains rupatadine as a second-generation antihistamine, has excellent plaster physical properties, good adhesion to applied skin, and good transdermal absorption of rupatadine as an active ingredient is provided. The external patch containing rupatadine uses an acrylic adhesive as an adhesive base. Specifically, the external patch containing rupatadine uses an acrylic adhesive as an adhesive base and further contains an organic acid having 2 to 7 carbon atoms as a solubilizer, a fatty acid ester as a softener, and/or a surfactant.